← All Durect CORP filings

Durect CORP 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

DRRX
Durect CORP
10-K: DURECT Corporation's 10-K Filing: Focus on Larsucosterol Development and Strategic Shifts
DURECT Corporation's 10-K filing highlights the company's focus on larsucosterol for alcohol-associated hepatitis (AH), the termination of the Innocoll agreement, and the sale of the ALZET product line.
DRRX
Durect CORP
10-K: DURECT Corporation Outlines Securities and Warrants in 10-K Filing
DURECT Corporation's 10-K filing details the company's common stock, preferred stock, and outstanding warrants, including terms, voting rights, and anti-takeover provisions.